Telixの第3相ZIRCON試験では,米国限定承認プロセスでTLX250- CDxで腎臓がんの高精度検出が示されました. Telix's Phase III ZIRCON trial showed high-accuracy detection of kidney cancer with TLX250-CDx in US-bound approval process.

Telix Pharmaceuticalsは,ザ・ランセット・オンコロジー誌に掲載された第3相ZIRCON試験の有望な結果を発表しました. Telix Pharmaceuticals announced promising results from its Phase III ZIRCON trial, published in The Lancet Oncology. 検査中のPET剤TLX250- CDx (Zircaix®) は,未定の腎臓の質量を有する患者におけるクリアセル腎臓細胞癌 (ccRCC) の検出に高い精度を示し,感度86%と特異性87%を達成した. The investigational PET agent TLX250-CDx (Zircaix®) demonstrated high accuracy in detecting clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses, achieving 86% sensitivity and 87% specificity. FDAが承認すれば 米国で利用可能な 腎臓がんの標的型PET剤となるでしょう If approved by the FDA, it would be the first targeted PET agent for kidney cancer available in the U.S.